{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T21:01:42Z","timestamp":1793826102407,"version":"4.6.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"7832","license":[{"start":{"date-parts":[[2020,10,21]],"date-time":"2020-10-21T00:00:00Z","timestamp":1603238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,10,21]],"date-time":"2020-10-21T00:00:00Z","timestamp":1603238400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nature"],"published-print":{"date-parts":[[2020,11,5]]},"DOI":"10.1038\/s41586-020-2850-3","type":"journal-article","created":{"date-parts":[[2020,10,21]],"date-time":"2020-10-21T12:03:31Z","timestamp":1603281811000},"page":"121-125","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":235,"title":["Cancer immunotherapy via targeted TGF-\u03b2 signalling blockade in TH cells"],"prefix":"10.1038","volume":"587","author":[{"given":"Shun","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mytrang H.","family":"Do","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun","family":"Chou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efstathios G.","family":"Stamatiades","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Briana G.","family":"Nixon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengyu","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristelle J.","family":"Capistrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6323-5171","authenticated-orcid":false,"given":"Nai-Kong V.","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1383-0535","authenticated-orcid":false,"given":"Ming O.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,21]]},"reference":[{"key":"2850_CR1","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1038\/nm1009-1158","volume":"15","author":"CL Sawyers","year":"2009","unstructured":"Sawyers, C. L. Shifting paradigms: the seeds of oncogene addiction. Nat. Med. 15, 1158\u20131161 (2009).","journal-title":"Nat. Med."},{"key":"2850_CR2","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1016\/j.cell.2015.08.047","volume":"162","author":"JP Allison","year":"2015","unstructured":"Allison, J. P. Checkpoints. Cell 162, 1202\u20131205 (2015).","journal-title":"Cell"},{"key":"2850_CR3","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.molmed.2018.12.009","volume":"25","author":"AJ Sabnis","year":"2019","unstructured":"Sabnis, A. J. & Bivona, T. G. Principles of resistance to targeted cancer therapy: lessons from basic and translational cancer biology. Trends Mol. Med. 25, 185\u2013197 (2019).","journal-title":"Trends Mol. Med."},{"key":"2850_CR4","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","volume":"168","author":"P Sharma","year":"2017","unstructured":"Sharma, P., Hu-Lieskovan, S., Wargo, J. A. & Ribas, A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell 168, 707\u2013723 (2017).","journal-title":"Cell"},{"key":"2850_CR5","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1056\/NEJM197108122850711","volume":"285","author":"J Folkman","year":"1971","unstructured":"Folkman, J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285, 1182\u20131186 (1971).","journal-title":"N. Engl. J. Med."},{"key":"2850_CR6","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nature10144","volume":"473","author":"P Carmeliet","year":"2011","unstructured":"Carmeliet, P. & Jain, R. K. Molecular mechanisms and clinical applications of angiogenesis. Nature 473, 298\u2013307 (2011).","journal-title":"Nature"},{"key":"2850_CR7","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1038\/nrc2442","volume":"8","author":"G Bergers","year":"2008","unstructured":"Bergers, G. & Hanahan, D. Modes of resistance to anti-angiogenic therapy. Nat. Rev. Cancer 8, 592\u2013603 (2008).","journal-title":"Nat. Rev. Cancer"},{"key":"2850_CR8","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/j.cell.2019.01.021","volume":"176","author":"RS Apte","year":"2019","unstructured":"Apte, R. S., Chen, D. S. & Ferrara, N. VEGF in signaling and disease: beyond discovery and development. Cell 176, 1248\u20131264 (2019).","journal-title":"Cell"},{"key":"2850_CR9","doi-asserted-by":"publisher","unstructured":"Liu, M. et al. TGF-\u03b2 suppresses type 2 immunity to cancer. Nature https:\/\/doi.org\/10.1038\/s41586-020-2836-1 (2020).","DOI":"10.1038\/s41586-020-2836-1"},{"key":"2850_CR10","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.cell.2016.12.022","volume":"168","author":"MH Spitzer","year":"2017","unstructured":"Spitzer, M. H. et al. Systemic immunity is required for effective cancer immunotherapy. Cell 168, 487\u2013502 (2017).","journal-title":"Cell"},{"key":"2850_CR11","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/j.celrep.2014.06.059","volume":"8","author":"N Rigamonti","year":"2014","unstructured":"Rigamonti, N. et al. Role of angiopoietin-2 in adaptive tumor resistance to VEGF signaling blockade. Cell Rep. 8, 696\u2013706 (2014).","journal-title":"Cell Rep."},{"key":"2850_CR12","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.4049\/jimmunol.149.5.1779","volume":"149","author":"LC Burkly","year":"1992","unstructured":"Burkly, L. C. et al. Inhibition of HIV infection by a novel CD4 domain 2-specific monoclonal antibody. Dissecting the basis for its inhibitory effect on HIV-induced cell fusion. J. Immunol. 149, 1779\u20131787 (1992).","journal-title":"J. Immunol."},{"key":"2850_CR13","doi-asserted-by":"publisher","first-page":"6935","DOI":"10.1128\/JVI.00453-10","volume":"84","author":"R Song","year":"2010","unstructured":"Song, R. et al. Epitope mapping of ibalizumab, a humanized anti-CD4 monoclonal antibody with anti-HIV-1 activity in infected patients. J. Virol. 84, 6935\u20136942 (2010).","journal-title":"J. Virol."},{"key":"2850_CR14","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1038\/nm.2328","volume":"17","author":"MJ Bissell","year":"2011","unstructured":"Bissell, M. J. & Hines, W. C. Why don\u2019t we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nat. Med. 17, 320\u2013329 (2011).","journal-title":"Nat. Med."},{"key":"2850_CR15","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.pbiomolbio.2012.05.001","volume":"110","author":"S Huang","year":"2012","unstructured":"Huang, S. Tumor progression: chance and necessity in Darwinian and Lamarckian somatic (mutationless) evolution. Prog. Biophys. Mol. Biol. 110, 69\u201386 (2012).","journal-title":"Prog. Biophys. Mol. Biol."},{"key":"2850_CR16","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1056\/NEJM198612253152606","volume":"315","author":"HF Dvorak","year":"1986","unstructured":"Dvorak, H. F. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N. Engl. J. Med. 315, 1650\u20131659 (1986).","journal-title":"N. Engl. J. Med."},{"key":"2850_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.1001674","volume":"11","author":"A Sledzi\u0144ska","year":"2013","unstructured":"Sledzi\u0144ska, A. et al. TGF-\u03b2 signalling is required for CD4+ T cell homeostasis but dispensable for regulatory T cell function. PLoS Biol. 11, e1001674 (2013).","journal-title":"PLoS Biol."},{"key":"2850_CR18","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.immuni.2011.04.019","volume":"35","author":"MK Donkor","year":"2011","unstructured":"Donkor, M. K. et al. T cell surveillance of oncogene-induced prostate cancer is impeded by T cell-derived TGF-\u03b21 cytokine. Immunity 35, 123\u2013134 (2011).","journal-title":"Immunity"},{"key":"2850_CR19","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.18632\/oncotarget.403","volume":"2","author":"A Sarkar","year":"2011","unstructured":"Sarkar, A., Donkor, M. K. & Li, M. O. T cell- but not tumor cell-produced TGF-\u03b21 promotes the development of spontaneous mammary cancer. Oncotarget 2, 1339\u20131351 (2011).","journal-title":"Oncotarget"},{"key":"2850_CR20","doi-asserted-by":"publisher","first-page":"162","DOI":"10.4161\/onci.1.2.18481","volume":"1","author":"MK Donkor","year":"2012","unstructured":"Donkor, M. K., Sarkar, A. & Li, M. O. TGF-\u03b21 produced by activated CD4+ T cells antagonizes T cell surveillance of tumor development. OncoImmunology 1, 162\u2013171 (2012).","journal-title":"OncoImmunology"},{"key":"2850_CR21","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1002\/j.1460-2075.1993.tb05798.x","volume":"12","author":"N Killeen","year":"1993","unstructured":"Killeen, N., Sawada, S. & Littman, D. R. Regulated expression of human CD4 rescues helper T cell development in mice lacking expression of endogenous CD4. EMBO J. 12, 1547\u20131553 (1993).","journal-title":"EMBO J."},{"key":"2850_CR22","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1146\/annurev-pathol-012513-104720","volume":"9","author":"GL Semenza","year":"2014","unstructured":"Semenza, G. L. Oxygen sensing, hypoxia-inducible factors, and disease pathophysiology. Annu. Rev. Pathol. 9, 47\u201371 (2014).","journal-title":"Annu. Rev. Pathol."},{"key":"2850_CR23","doi-asserted-by":"publisher","first-page":"11393","DOI":"10.1073\/pnas.172398299","volume":"99","author":"J Holash","year":"2002","unstructured":"Holash, J. et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc. Natl Acad. Sci. USA 99, 11393\u201311398 (2002).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2850_CR24","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1038\/nri2808","volume":"10","author":"RA Flavell","year":"2010","unstructured":"Flavell, R. A., Sanjabi, S., Wrzesinski, S. H. & Licona-Lim\u00f3n, P. The polarization of immune cells in the tumour environment by TGF\u03b2. Nat. Rev. Immunol. 10, 554\u2013567 (2010).","journal-title":"Nat. Rev. Immunol."},{"key":"2850_CR25","doi-asserted-by":"publisher","first-page":"a022285","DOI":"10.1101\/cshperspect.a022285","volume":"9","author":"MW Pickup","year":"2017","unstructured":"Pickup, M. W., Owens, P. & Moses, H. L. TGF-\u03b2, bone morphogenetic protein, and activin signaling and the tumor microenvironment. Cold Spring Harb. Perspect. Biol. 9, a022285 (2017).","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"2850_CR26","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.trecan.2016.11.008","volume":"3","author":"S Colak","year":"2017","unstructured":"Colak, S. & Ten Dijke, P. Targeting TGF-\u03b2 signaling in cancer. Trends Cancer 3, 56\u201371 (2017).","journal-title":"Trends Cancer"},{"key":"2850_CR27","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/j.immuni.2019.03.024","volume":"50","author":"E Batlle","year":"2019","unstructured":"Batlle, E. & Massagu\u00e9, J. Transforming growth factor-\u03b2 signaling in immunity and cancer. Immunity 50, 924\u2013940 (2019).","journal-title":"Immunity"},{"key":"2850_CR28","doi-asserted-by":"publisher","first-page":"eaan5488","DOI":"10.1126\/scitranslmed.aan5488","volume":"10","author":"Y Lan","year":"2018","unstructured":"Lan, Y. et al. Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-\u03b2. Sci. Transl. Med. 10, eaan5488 (2018).","journal-title":"Sci. Transl. Med."},{"key":"2850_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-02696-6","volume":"9","author":"R Ravi","year":"2018","unstructured":"Ravi, R. et al. Bifunctional immune checkpoint-targeted antibody-ligand traps that simultaneously disable TGF\u03b2 enhance the efficacy of cancer immunotherapy. Nat. Commun. 9, 741 (2018).","journal-title":"Nat. Commun."},{"key":"2850_CR30","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1016\/j.cell.2019.10.029","volume":"179","author":"S Jiao","year":"2019","unstructured":"Jiao, S. et al. Differences in tumor microenvironment dictate T helper lineage polarization and response to immune checkpoint therapy. Cell 179, 1177\u20131190 (2019).","journal-title":"Cell"},{"key":"2850_CR31","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/j.immuni.2010.04.012","volume":"32","author":"W Ouyang","year":"2010","unstructured":"Ouyang, W., Beckett, O., Ma, Q. & Li, M. O. Transforming growth factor-\u03b2 signaling curbs thymic negative selection promoting regulatory T cell development. Immunity 32, 642\u2013653 (2010).","journal-title":"Immunity"},{"key":"2850_CR32","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1126\/science.1252510","volume":"344","author":"RA Franklin","year":"2014","unstructured":"Franklin, R. A. et al. The cellular and molecular origin of tumor-associated macrophages. Science 344, 921\u2013925 (2014).","journal-title":"Science"},{"key":"2850_CR33","doi-asserted-by":"publisher","first-page":"E7536","DOI":"10.1073\/pnas.1706356114","volume":"114","author":"SA Oh","year":"2017","unstructured":"Oh, S. A. et al. Foxp3-independent mechanism by which TGF-\u03b2 controls peripheral T cell tolerance. Proc. Natl Acad. Sci. USA 114, E7536\u2013E7544 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2850_CR34","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1073\/pnas.1120059109","volume":"109","author":"H Mouquet","year":"2012","unstructured":"Mouquet, H., Warncke, M., Scheid, J. F., Seaman, M. S. & Nussenzweig, M. C. Enhanced HIV-1 neutralization by antibody heteroligation. Proc. Natl Acad. Sci. USA 109, 875\u2013880 (2012).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2850_CR35","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S1097-2765(00)80120-3","volume":"2","author":"S Zhou","year":"1998","unstructured":"Zhou, S., Zawel, L., Lengauer, C., Kinzler, K. W. & Vogelstein, B. Characterization of human FAST-1, a TGF-\u03b2 and activin signal transducer. Mol. Cell 2, 121\u2013127 (1998).","journal-title":"Mol. Cell"},{"key":"2850_CR36","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1038\/357695a0","volume":"357","author":"NA Clipstone","year":"1992","unstructured":"Clipstone, N. A. & Crabtree, G. R. Identification of calcineurin as a key signalling enzyme in T-lymphocyte activation. Nature 357, 695\u2013697 (1992).","journal-title":"Nature"}],"container-title":["Nature"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41586-020-2850-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-020-2850-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-020-2850-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T04:18:05Z","timestamp":1696911485000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41586-020-2850-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,21]]},"references-count":36,"journal-issue":{"issue":"7832","published-print":{"date-parts":[[2020,11,5]]}},"alternative-id":["2850"],"URL":"https:\/\/doi.org\/10.1038\/s41586-020-2850-3","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.738871118.793584893","asserted-by":"object"}]},"ISSN":["0028-0836","1476-4687"],"issn-type":[{"value":"0028-0836","type":"print"},{"value":"1476-4687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,21]]},"assertion":[{"value":"20 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Memorial Sloan Kettering Cancer Center has filed a patent application with the U.S. Patent and Trademark Office directed toward methods and compositions for targeting TGF-\u03b2 signaling in CD4<sup>+<\/sup> helper T cell for cancer immunotherapy.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}